On April 30, 2024 Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, reported that it has entered into a research collaboration with Bristol Myers Squibb (NYSE: BMY) to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion (Press release, Scenic Biotech, APR 30, 2024, View Source [SID1234642469]). Under the terms of the agreement, Scenic Biotech will be entitled to an upfront payment and potential additional payments contingent upon achievement of a range of research, development and commercial milestones. No further financial details have been disclosed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Working with a world leader in drug discovery and development is an important validation of our Cell-Seq platform’s unique capability to link cellular pathways to drug targets," commented Oscar Izeboud, PhD, CEO of Scenic Biotech. "As we continue to advance our own pipeline of first-in-class disease-modifying therapies, we remain committed to harnessing the power of our ground-breaking approach to support our collaborators in crafting innovative medicines for patients with devastating conditions."
The collaboration with Bristol Myers Squibb marks Scenic Biotech’s second strategic collaboration with a major industry partner, following the multi-year genetic modifier collaborative agreement with Genentech announced in 2020. Both collaborations leverage the Cell-Seq platform’s ability to provide genetic insights leading to the discovery and development of novel therapeutics. While Scenic primarily focuses on applying its Cell-Seq technology to identify modifier genes, the technology has demonstrated its ability to map previously unexplored biological pathways and investigate disease biology.